Introduction: The aim of this study was to investigate the potential role of a
Introduction
Alzheimer's disease (AD) is an age-related neurodegenerative disorder that is characterized by progressive memory loss and deteriorated higher cognitive functions .
Increasing evidence suggests that the pathophysiological process of AD begins well before the diagnosis of clinical dementia (Ritchie et al, 2016) . The majority of AD patients are asymptomatic during the preclinical stages of the pathological process which is believed to be a period of approximately 17 years (Villemagne et al, 2013) .
Therefore, development of early and accurate diagnosis for AD is crucial, enabling accurate diagnoses and facilitating the possibility for an early and specialized treatment to slow or delay the progression of the disease and provide prognostic information. Current methods for diagnosing AD involve a detailed history and neuropsychological testing to establish the presence of dementia, and a definitive diagnosis of AD can only be made postmortem. The new diagnostic methods based on imaging techniques and analysis of proteins and other components in the cerebrospinal fluid (CSF) have been developed recently (Fagan et al, 2011; Sepulcre & Masdeu, 2016; Wang et al, 2015) . These methods, however, are not suitable for the everyday clinical screening due to their invasiveness and relatively high cost. Thus, the identification of reliable, non-invasive and inexpensive biomarkers is a major challenge before or during the pre-clinical phase in order to diagnose and monitor AD progression and enable early treatments to slow or delay the progression of the disease.
Mild cognitive impairment (MCI) is defined as the intermediary state between normal 4 old age cognition and AD (Winblad et al, 2004) , which reflects preclinical AD in a considerable portion of the affected individuals. Patients with MCI have high risk of developing AD with conversion rates about 12% annually and 80% at six years follow-up (Petersen, 2004) . Consequently MCI may be a useful AD prodromal phase in which to test putative biomarkers for their efficacy in early disease detection.
MicroRNAs are a group of small noncoding RNAs that modify gene expression at the post-transcriptional level. Thus, microRNAs are important epigenetic regulators of numerous cellular processes (Bartel, 2009; McNeill & Van Vactor, 2012) . In the past years, microRNAs have gained increasing attention in studies on neurodegenerative diseases. Recently, circulating microRNA levels have been proposed as potential diagnostic tools for a number of diseases Zhou et al, 2011) .
Accumulating evidences of microRNA expression profiles reported by several groups showed that microRNAs were involved in AD progressions (Muller et al, 2014; van Harten et al, 2015) and altered in response to Aβ indicating that microRNA and AD had a direct link (Schonrock et al, 2010; Sorensen et al, 2016) . However, those studies were limited by one or more of the following factors: limited number of screened microRNAs, small sample size, and lack of independent validation. Importantly, cellfree microRNAs have been shown to be stable in blood samples (Mitchell et al, 2008) , which laid the foundation for studying the role of serum/plasma microRNAs in the diagnosis and prognosis of disease.
In this study, we aimed to investigate serum microRNA expression profiles (877 microRNAs) with independent validation in a large cohort of 202 participants, with 5 the intention to identify a panel of microRNAs for the early diagnosis of AD, thus to explore their clinical significance in disease development and progression, and provide information for personalized therapy.
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Results
MicroRNA screening and testing
The strategy of identifying differential microRNAs for early diagnosis of AD in this study was to choose candidate microRNAs on the basis of pairwise comparison of AD versus cognitive normal control (CNC), AD versus MCI, and MCI versus CNC, respectively. The serum samples that met the eligibility criteria were allocated to the discovery, training and validation phases (Figure 1 ). The characteristics of study participants in three phases were listed in Table 1 . Expression profiling of microRNAs of sixty serum samples in CNC, MCI and AD was performed using the Agilent microRNA microarrays containing 877 human microRNA probe sets, which has been shown to produce precise and accurate measurements of microRNA levels that span a linear dynamic range from 0.2 amol to 2 fmol of input microRNA and good correlation to Taqman assay (Fumiaki Sato, 2009 ). Hierarchical clustering of microRNA expression profiles in three group comparisons was illustrated in Supplement Figure 1 . A Mann-Whitney test was performed to discover differentially expressed microRNAs in the three pairwise comparisons: MCI and AD versus CNC respectively. Significance analysis resulted in the identification of eighty two microRNAs as differentially expressed among the CNC, MCI and AD groups (Supplement Table 1A -1C) . From the differentially expressed microRNAs, 29 detectable microRNAs with P value < 0.05 and fold expression change > 2 were identified between the MCI and CNC groups (Supplement Table 1A ), 23 detectable microRNAs with P value < 0.05 and fold expression change > 2 were identified 7 between the AD and CNC groups (Supplement Table 1B) , and 30 detectable microRNAs with P value < 0.001 and fold expression change > 2 were identified between the AD and MCI groups (Supplement Table 1C ). There was twelve microRNAs overlapping between the three group comparisons. Finally, 14 microRNAs with P value < 0.037 and fold change > 2.6 from the 70 differentially expressed microRNAs were selected for further validation by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), with cohort of 30 participants (Supplement Table 1D ).
Differential expression profile of four candidate microRNAs
The 14 selected microRNAs were first tested using an independent cohort of 30 serum samples with qRT-PCR, and five microRNAs (let-7g, miR-197, miR-126, miR-29a and miR-451) of 14 passed the quality control. The expression levels of four microRNAs (let-7g, miR-197, miR-126 and miR-29a) were significantly lower in the serum of AD and MCI when compared with CNC group (Figure 2 ). The expression profile of those four individual microRNAs was further evaluated with qRT-PCR on 120 additional serum samples. The combined 150 serum samples were used as the training data set for the construction of the diagnostic microRNA panel for the differentiation not only between the AD group and the CNC group but also between the MCI group and the CNC group.
MicroRNA expression profile for MCI versus CNC and AD versus CNC in the training data set
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The four differentially expressed microRNAs (let-7g, miR-197, miR-126, miR-29a) were evaluated in serum samples of the training data set (150 participants). Scatterplots of expressions of the four microRNAs in CNC, MCI, and AD were illustrated in Table 2 ). The accuracy of let-7g, miR-197, miR-126 and miR-29a for diagnosing MCI from CNC, measured by AUC, was 0.71, 0.68, 0.68, and 0.72, respectively, and the multivariate P values for both miR-197 and miR-126 were < 0.05 (Supplement Table 2 ). Similar trend of lower microRNA expressions was also found in patients with AD compared with those in CNC group (P<0.0001~0.05) ( Figure 2 ) and fold changes were 0.3, 0.3, 0.4, and 0.4 for let-7g, miR-197, miR-126, and miR-29a, respectively (Supplement Table 3 ). The corresponding AUCs of let-7g, miR-197, miR-126 and miR-29a in differentiating AD from CNC were 0.71, 0.71, 0.70, and 0.67, respectively (Supplement Table 3 ). Because age is acting as confounding factor in AD, the relation between age and expression of the four microRNAs was studied with the Pearson correlation analysis. The results showed that there were no significant correlations of the expressions of let-7g, miR-197, miR-126 and miR-29a with age ( Figure 3 Figure 5A ) and the AUC of the microRNA panel on diagnosing AD from CNC was 0.77 (95% CI, 0.68 to 0.86) with 92.0% sensitivity and 50.0% specificity ( Figure   5B ). Then the microRNA panel (let-7g, miR-197, miR-126, miR-29a) sensitivity and 97.9% specificity in differentiating MCI from CNC ( Figure 5C ) and the AUC for the microRNA panel combined with MMSE score on diagnosing AD from CNC was increased to 0.99 (95% CI, 0.96 to 1.00) with 97.9% sensitivity and 97.9% specificity ( Figure 5D ).
Validating the microRNA panel
The parameters estimated from the training data set were used to predict the probability of being clinically diagnosed with MCI and AD from CNC for the independent validation data set (fifty two participants, eighteen participants from CNC and MCI group, sixteen participants from AD group). The predicted probability was used to construct the ROC curve. The AUC of the four microRNA panel (let-7g, miR-197, miR-126 and miR-29a) was 0.82 (95%CI, 0.68 to 0.96) with 88.9% sensitivity and 66.7% specificity in differentiating between MCI and CNC ( Figure 6A ) and the AUC of the microRNA panel on diagnosing AD from CNC was 0.82 (95%CI, 0.69 to 0.96) with 81.3% sensitivity and 66.7% specificity ( Figure 6B ). When combined with MMSE score, the AUC of the microRNA panel in differentiating between MCI and AD from CNC were was further improved to 0.91 and 1.00 ( Figure   6C and 6D).
MicroRNAs target genes prediction and Pathway enrichment
To determine possible target genes for the differentially expressed microRNAs, we searched the TargetScan -7g, miR-29a, miR-126 and miR-197) . Two hundred and thirty one microRNA target genes were cross validated from both TargetScan and Pictar (Supplement Table 4 ). Thus, the results suggested that the human microRNA target genes regulated by an individual microRNA generally constitutes the biological network of functionally-associated molecules (Satoh & Tabunoki, 2011 Table 5 ). These results suggested an existence of collaborative regulation of gene expression by transcription factors and microRNAs in cancer-associated microRNA target gene networks.
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Discussion
Though several methods have been developed to alleviate the symptoms of AD, no therapies have been developed that can modify the course of the disease (Huang & Mucke, 2012 ). This stems not only from a lack of a detailed understanding of the pathophysiological processes underpinning the disease, but also an inability to diagnose patients both accurately and early. It has been estimated that about twothirds of dementia patients go undiagnosed (Ho et al, 2010) , and that by the time of diagnosis AD pathology has been developing for∼20 years (Villemagne et al, 2013) .
Thus biomarkers that can diagnose AD accurately and early are urgently needed to improve the diagnostic sensitivity and specificity and to monitor the biological activity of AD in terms of the burden of neuronal involvement and the rate of disease progression.
Current methods for the diagnosis of AD depend on a combination of brain imaging and tests of cerebrospinal fluid (CSF) and blood to identify changes that signal AD.
However, the imaging techniques do not afford sufficient accuracy in discriminating between AD and non-AD, especially between MCI and non-AD dementia to provide clear and decisive diagnosis (Morris et al, 2016) and wide variations in sensitivity and specificity have been reported. The diagnostic use of CSF is limited because of invasive collection and the potential side effects by lumbar puncture. Thus, the ability to identify biomarkers through less invasive procedures, such as in a blood test, would be significant. Circulating serum microRNA might represent a novel putative, easily accessible and stable marker. The recent discovery of aberrant expression of 14 microRNAs in AD provided clues for analyzing circulating microRNAs for AD diagnosis.
In this study, we revealed that the expression levels of let-7g, miR-197, miR-126 and miR-29a in serum were decreased significantly in MCI and AD group than those of CNC group. Furthermore, the expression levels of the four microRNAs were correlated with MMSE score, which suggested that they were potential circulating biomarkers for diagnosing MCI and AD. The microRNA panel with the four microRNAs from the multivariate logistic regression model demonstrated good diagnostic performance in differentiating MCI and AD from CNC. When combined with MMSE score, the diagnostic performance of the microRNA panel was further improved.
Among the microRNA panel with four microRNAs observed in our study, only miR-29 has been previously reported the association with AD. Several groups have revealed changes in miR-29 expression levels in the AD brain, where a decrease in miR-29 was observed in most of the studies (Lugli et al, 2015; Shioya M, 2010) . This decrease was also observed in the cerebral cortex of transgenic mice bearing APP and PS1 familial AD mutations (Wang et al, 2009 ). Interestingly, miR-29 has been shown to target BACE1 which is directly implicated in AD pathogenesis through the formation of toxic Aβ peptides in vitro and in vivo (Hebert et al, 2008; Lei et al, 2015) . These observations suggest a potential role for miR-29 in the pathogenesis of AD. Besides miR-29, the other three microRNAs (let-7g, miR-197, and miR-126) have not been identified or investigated in relationship to AD till now. Only one 15 research reported that miR-197 was downregulated in white matter, let-7g and miR-126 were downregulated in gray matter of AD (Zong et al, 2011). Moreover, miR-197 was also found differentially expressed in cerebral spinal fluid of AD patients (Cogswell et al, 2008) . MiR-126 is highly enriched in endothelial cells and plays a pivotal role in maintaining endothelial homeostasis and vascular integrity (Wang et al, 2008) , regulating expression of adhesion molecules and controlling vascular inflammation (Harris et al, 2008) . High expression of miR-126 has been reported in the human and rodent brain (Landgraf et al, 2007) and in cultured rat motoneurons (Wei et al, 2010) indicated that it could play a role in neuronal cell function. Potential role of miR-126 in the nervous disorders could be related with its profound impact on regulating factors in key signaling pathways that are associated with disease processes.
For example, miR-126 is involved in insulin-like growth factor (IGF)-1, vascular epithelial growth factor or EGF-like domain containing protein 7 (EGFL7) signaling.
Insulin/IGF-1 signaling promotes neurite sprouting, synapse formation, and neuronal survival, and it has been implicated in memory, aging, and neurodegeneration (Bishop et al, 2010) . In AD, neurons are resistant to IGF-1 and there is a large body of data linking changes in growth factor/ IGF-1 signaling to disease pathogenesis and altered neuronal cell function (Freude et al, 2009) . Another way that miR-126 functions in the nervous system could be through its genomic and regulatory link with EGFL7 (Sonntag et al, 2012) . MiR-126 is encoded in intron 7 of the EGFL7 gene and originates from the EGFL7 pre-mRNA (Wang et al, 2008) . EGFL7 is expressed in the mammalian brain where it regulates notch signaling in neural stem cells altering their 16 self-renewal and multipotency as well as their differentiation potential toward neuroand gliogenesis (Schmidt et al, 2009 ). EGFL7 could have implication for boosting adult neurogenesis as a repair mechanism in neurodegenerative disorders and brain injury (Bicker & Schmidt, 2010) . Although it remains to be determined whether miR-126 is involved in these processes, given its impact on IGF-1 and EGFL7 regulation in a magnitude of cell systems, it is likely that similar mechanisms also occur in neurons.
Because a single microRNA concurrently downregulates hundreds of target mRNAs, the set of microRNA target genes coregulated by an individual microRNA generally constitutes the biologically integrated network of functionally associated molecules (Hsu et al, 2008; Satoh & Tabunoki, 2011 (KC, 2010; Wu et al, 2008) . This phenomenon was also observed in our results. Mir-197 and let-7g are involved in cancer initiation and progression, which were identified by several studies (Hamada et al, 2013; Kumar et al, 2008) . In our study, their expressions were decreased significantly in MCI and AD group than those of CNC group. The aberrant expressions of mir-197 and let-7g in human AD brain indicated that they might play crucial roles in AD as well as cancer (Hebert et al, 2008; Zong et al, 2011) . The increasing evidences for overlapping microRNA functions in cancer and neurodegeneration (Du & Pertsemlidis, 2011) suggest that microRNAs play multiple regulatory roles in pathways active across both diseases and the molecular machinery involved in maintaining neural function in neurodegenerative disease may be shared with oncogenic pathways (Saito & Saito, 2012) . MicroRNAs appear to be important in the common signaling pathways that regulate differentiation, proliferation and death of cells in both cancer and AD and may function using some of the same mechanisms (Holohan et al, 2012) . Some results indicate that chromatin remodeling by epigenetic treatment can directly modulate expression of microRNAs that are involved in the pathogenesis of cancer and neurodegenerative disease.
Nevertheless, there are very little functional data of mir-197 and let-7g in the central nervous system, much work remains to be accomplished to elucidate the roles of them in both normal and AD status.
To date, it is becoming clear that the consideration of a single biomarker might not be potent enough to improve diagnostic specificity. It seems probable that only the combination of several biomarkers derived from blood will be successful to define a patient-specific signature (Humpel, 2011) . Thus, circulating microRNAs, especially microRNA panel may be used as a potential novel noninvasive biomarker for AD diagnosis and prognosis assessment. Although there is a long history of investigation of circulating mRNA molecules as potential biomarkers, blood-based microRNA studies are in their infancy. In this study, we revealed differentially expressed microRNAs in serum from MCI, AD patients and healthy controls in a large population-based cohort and construct microRNA panel that demonstrated good diagnostic performance for both MCI and AD. When combined with MMSE score, the diagnostic performance of the microRNA panel was further improved, which suggested that microRNA profile along with other biomarkers and cognitive tests could potentially provide a comprehensive and non-invasive methodology for the early diagnosis of AD. The result that the target genes pathways relating to various types of cancers demonstrated possible intersections between microRNA functions in cancer and AD, suggesting that a similar strategy could be useful in studying both AD and cancer. The microRNAs in cancer and AD could benefit from future research in both diseases. Although our study got encouraging results of serum microRNA panel in early diagnosis of AD, it must be noted that the blood serum samples used in this 19 study were only clinically diagnosed and further studies are necessary to assess their ability to discriminate them from other forms of dementia. In addition, independent validation of these microRNAs as biomarkers will also be required. Whether these microRNA profiles could provide conclusive diagnosis is currently unknown, nonetheless, microRNA profiles along with other biomarkers and cognitive tests could potentially provide a more comprehensive and early diagnosis and prognosis of AD. Therefore, further studies and additional work will be needed to assess the ability and applicability in the future.
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Materials and methods
Patients
The 60 Geriatric Hospital according to NINCDS/ADRDA criteria (McKhann G, 1984) and MCI according to the Petersen criteria (Petersen et al, 1999) .
Study Design
This study included three phases. In each study phase, blood samples were obtained from participants including CNC, MCI and AD patients. Studies were approved by the Ethics Committee of Chinese PLA general Hospital and Beijing Geriatric Hospital.
Informed consent was obtained from all participants.
Discovery phase
Sixty serum samples from CNC, MCI and AD patients, each with 877 microRNAs, were screened with a microarray platform. The patient characteristics were presented in Table 1 . A Mann-Whitney test was performed to discover differentially expressed microRNAs in the three pairwise comparisons: CNC versus AD and MCI, respectively.
From the 8 differentially expressed microRNAs, fourteen detectable microRNAs with fold change > 2.6 and P value < 0.037 were tested by qRT-PCR, with cohort of thirty participants.
Training phase
The 14 microRNAs discovered via microarray were first tested with qRT-PCR in an independent cohort of serum samples from 30 participants. Five microRNAs (let-7g, miR-197, miR-126, miR-29a and miR-451) were detected in all groups and passed the quality control. The expressions of miR-451 were not different in CNC, MCI and AD groups. Thus, four microRNAs (let-7g, miR-197, miR-126 and miR-29a) that were differentially expressed among AD, MCI and CNC groups were further tested in an additional 120 participants. Finally, the 150 participants were used as the training set to construct the diagnostic microRNA panel based on the logistic regression model for the differentiation not only between the AD group and the CNC group but also between the MCI group and the CNC group. The patient characteristics in the training phase were presented in Table 1 .
Validation phase
The parameters of the logistic model from the training phase were applied to an independent cohort of fifty two samples for validating the diagnostic performance of the selected microRNA panel. The patient characteristics in the validation phase were presented in Table 1 .
Blood serum collection and RNA Isolation
Whole blood was centrifugation at 1600 g for 15 min following 30 min of clotting at 
RNA isolation
Total RNA was extracted from the serum by using mirVana PARIS microRNA
Isolation kit according to the instructions from the manufacturer (Ambion, Austin, TX). The concentration was quantified by NanoDrop 1000 Spectrophotometer (NanoDrop Technologies, Waltham, MA).
Genome-wide microRNA analysis
Human microRNA microarrays (Agilent Technologies, Santa Clara, CA) were used in 60 serum samples (n=20 normal, n=20 MCI and n=20 AD) to compare the expression profiles. The microarray contains probes for 877 human microRNAs from Sanger database v.14.0. Each slide is formatted with eight identical arrays. Total RNA (100 ng) derived from plasma samples were labeled with Cy3. Microarray slides were scanned by XDR Scan (PMT100, PMT5). The labeling and hybridization were performed according to the protocols in the Agilent microRNA microarray system.
The microarray image information was converted into spot intensity values using Feature Extraction Software Rev. 9.5.3 (Agilent Technologies, Santa Clara, CA). The signal after background subtraction was exported directly into the GeneSpring GX10 23 software (Agilent Technologies, Santa Clara, CA). The raw signals obtained for single-color CY3 hybridization were normalized by a stable endogenous control miR-1228. After that, a log transform with base 2 was performed. A sample that showed intra-array coefficients of variation (CV) across replicated spots on an array above 15% or positive signals less than 5% was considered to be unreliable and excluded from further analysis. A detectable microRNA was defined as the microRNA had positive signals on microarrays in > 50% of plasma samples from any one of the four category subjects.
Quantitative RT-PCR
For testing of candidate microRNAs acquired on microarrays, qRT-PCR was performed using Taqman microRNA assays (Applied Biosystems, Foster City, CA).
Assays to quantify mature microRNAs were conducted using a Taqman 
MicroRNA target gene prediction
The TargetScan algorithm was used to identify predicted gene targets of the differentially expressed microRNAs. TargetScan was mainly selected because it predicted the highest number of known microRNA targets obtained from TarBase 5.0
(http://microrna.gr/ tarbase) in our subset of differentially expressed microRNAs (Papadopoulos et al, 2009 ).
Potential target genes of microRNA were analyzed by the currently available major prediction algorithms, including TargetScan (http://targetscan.org) and PicTar (http://pictar.bio.nyu.edu).
KEGG pathway
Pathway analyses of the differentially expressed genes were based on the Kyoto Encyclopedia of Genes and Genomes (KEGG). KEGG pathway database is a recognized and comprehensive database including all kinds of biochemistry pathways (Kanehisa & Goto, 2000) . In this work, the KEGG database was applied to investigate the enrichment analysis of the differentially expressed genes to find the biochemistry pathways which might be involved in the occurrence and development of AD.
Statistical analysis
For microarray analysis, the Mann-Whitney unpaired test was used for the three pairwise comparisons (AD vs CNC, MCI vs CNC, and MCI vs AD) . Can-Jun Ruan did the literature search, all experiments, study design, data collection, data statistical analysis, data interpretation, and writing the manuscript.
Xiao-Rui Cheng did data collection, data statistical analysis and data interpretation.
Lu-Ning Wang was principal investigator for the clinical cases recruitment and serum samples collection.
Ji-Ping Tan and Wei-Shan Wang recruited patients, and were responsible for collecting serum samples. 
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